Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by B. Riley

B. Riley upgraded shares of Cognition Therapeutics (NASDAQ:CGTX) from a neutral rating to a buy rating in a research note released on Thursday morning, Marketbeat Ratings reports. B. Riley currently has $1.50 price objective on the stock, up from their previous price objective of $1.00.

Other analysts also recently issued reports about the stock. HC Wainwright lifted their price objective on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday. Chardan Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Cognition Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $8.30.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX opened at $0.63 on Thursday. The firm has a market capitalization of $26.18 million, a PE ratio of -0.65 and a beta of 1.26. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The business’s fifty day moving average price is $0.48 and its two-hundred day moving average price is $0.92.

Institutional Trading of Cognition Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CGTX. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics during the third quarter valued at approximately $27,000. Mercer Global Advisors Inc. ADV boosted its stake in Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares in the last quarter. Sigma Planning Corp boosted its stake in Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares in the last quarter. Finally, CM Management LLC increased its position in shares of Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the period. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.